目的 探讨津力达颗粒联合格列本脲片治疗妊娠期糖尿病的临床疗效。方法 将邢台市中心医院在2023年3月—2024年12月收治的88例妊娠期糖尿病患者作为研究对象，按随机数字表法将患者分为对照组和治疗组，每组各44例。对照组患者口服格列本脲片，首次剂量2.5 mg/d，7 d后递增为5 mg/d，早午餐前口服，2.5 mg/次。治疗组在对照组基础上口服津力达颗粒，1袋/次，3次/d。两组患者持续治疗1个月。比较两组患者的临床疗效、血糖指标和血清指标。结果 治疗后，对照组的总有效率为77.27%，治疗组的总有效率为93.18%，组间比较差异有统计学意义（P＜0.05）。治疗后，两组的空腹血糖（FBG）、平均血糖波动幅度（MAGE）、胰岛素抵抗指数（HOMA-IR）均明显减小（P＜0.05），且治疗组的FBG、MAGE、HOMA-IR明显低于对照组（P＜0.05）。治疗后，两组的血清半乳糖凝聚素-13（Gal-13）、分泌型卷曲蛋白5（SFRP5）水平明显升高，血清成纤维细胞生长因子-21（FGF-21）水平明显降低（P＜0.05）；治疗组的血清Gal-13、SFRP5水平高于对照组，血清FGF-21水平低于对照组（P＜0.05）。结论 津力达颗粒联合格列本脲片可提高妊娠期糖尿病的临床疗效，明显降低血糖水平和胰岛素抵抗，调节血清Gal-13、SFRP5、FGF-21水平。

Objective To explore the clinical efficacy of Jinlida Granules combined with Glibenclamide Tablets in treatment of gestational diabetes mellitus. Methods A total of 88 patients with gestational diabetes mellitus who were admitted to Xingtai Central Hospital from March 2023 to December 2024 were divided into control group and treatment group according to the random number table method, with 44 cases in each group. Patients in the control group were po administered with Glibenclamide Tablets at an initial dose of 2.5 mg/d, which gradually increased to 5 mg/d after 7 d, and were taken orally before breakfast and lunch at a dose of 2.5 mg/time. The treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, 3 times daily. Two groups of patients received continuous treatment for one month. The clinical efficacy, blood glucose indicators, and serum indicators were compared between two groups. Results After treatment, the total effective rate of the control group was 77.27%, while the total effective rate of the treatment group was 93.18%, and the difference between the two groups was significant (P < 0.05). After treatment, FBG, MAGE, and HOMA-IR of both groups were significantly decreased (P < 0.05), and FBG, MAGE, and HOMA-IR of the treatment group were significantly lower than those of the control group (P < 0.05). After treatment, the serum levels of Gal-13 and SFRP5 in both groups were significantly increased, while the serum levels of FGF-21 were significantly decreased (P < 0.05). The serum levels of Gal-13 and SFRP5 in the treatment group were higher than those in the control group, while the serum level of FGF-21 was lower than that in the control group (P < 0.05). Conclusion Jinlida Granules and Glibenclamide Tablets can improve the clinical efficacy in treatment of gestational diabetes mellitus, significantly reduce blood glucose levels and insulin resistance, and regulate serum levels of Gal-13, SFRP5, and FGF-21.

R977

邢台市重点研发计划自筹项目（2022ZC110）